Genomic characterization of a new phage BUCT541 against *Klebsiella pneumoniae* K1-ST23 and efficacy assessment in mouse and *Galleria mellonella* larvae

Mingfang Pu¹, Yahao Li²*, Pengjun Han², Wei Lin¹, Ronghua Geng³, Fen Qu³, Xiaoping An¹, Lihua Song¹, Yigang Tong¹,², Shuyan Zhang⁴*, Zhen Cai⁵* and Huahao Fan¹*

¹College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, China, ²Beijing Advanced Innovation Center for Soft Matter Science and Engineering (BAIC-SM), Beijing University of Chemical Technology, Beijing, China, ³Aviation General Hospital, Beijing, China, ⁴Department of Medical Technology Support, Jingdong Medical District of Chinese People’s Liberation Army of China General Hospital, Beijing, China

Over the past decades, the spread of multi-drug-resistant *Klebsiella pneumoniae* (MDR-KP) is becoming a new threat and new effective therapies against this pathogen are needed. Bacteriophage (phage) therapy is considered to be a promising alternative treatment for MDR-KP infections compared with antibacterial drug usage. Here, we reported a new phage BUCT541 which can lyse MDR-KP ST23. The genome of BUCT541 is a double-stranded linear 46,100-bp long DNA molecule with 48% GC content through the Next generation sequencing (NGS) data. A total of 81 open reading frames and no virulence or antimicrobial resistance genes are annotated in the BUCT541 genome. BUCT541 was able to lyse 7 of the 30 tested MDR-KP according to the host range analysis. And the seven sensitive strains belonged to the *K. pneumoniae* K1-ST23. BUCT541 exhibited high thermal stability (4–70°C) and broad pH tolerance (pH 3–11) in the stability test. The *in vivo* results showed that BUCT541 (4 × 10⁷ plaque-forming units (PFU)/each) significantly increased the survival rate of *K. pneumoniae* infected *Galleria mellonella* from 5.3% to 83.3% within 48h. Moreover, in the mouse lung infection model, high doses of BUCT541 (2 × 10⁷ PFU/each) cured 100% of BALB/c mice that were infected with *K. pneumoniae*. After 30 h of treatment with phage BUCT541 of the multiplicity of infection (MOI) = 10, the *K. pneumoniae* in the lungs of mice was lower than 10⁴ CFU/mL compared to the control group 10⁹ CFU/mL. Together, these findings indicate that phage BUCT541 holds great promise as an alternative therapy with excellent stability and a wide lysis range for the treatment of MDR-KP ST23 infection.

**KEYWORDS**
bacteriophage (phage) therapy, phage BUCT541, MDR-KP K1-ST23, *Galleria mellonella*, BALB/c mice

---

*Correspondence* Huahao Fan fanhuahao@mail.buct.edu.cn

© 2022 Pu, Li, Han, Geng, Qu, An, Song, Tong, Zhang, Cai and Fan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
Introduction

*Klebsiella pneumoniae* is an opportunistic hospital-acquired pathogen that causes serious hospital infections, especially in immunocompromised patients (Califore, 2010; Wang et al., 2020). As the second-ranked hospital-acquired pathogen, *K. pneumoniae* can parasitize the intestines, lungs, and skin (Rees et al., 2016; Marques et al., 2019; Zaki, 2019) to cause serious infections such as urinary tract infections, lung infections, bloodstream infections, and sepsis (Mazzariol et al., 2017; Ishiguro et al., 2020). The β-lactam antibiotics are used for *K. pneumoniae* infections, but with the prevalence of extended-spectrum-lactamases (ESBLs)-producing *K. pneumoniae*, carbapenems have become first-line antibiotics to treat *K. pneumoniae* infection (Grillon et al., 2016; Mikhail et al., 2019). In 1999, the carbapenem-resistant *K. pneumoniae* (CR-kpn) strain was first observed (Koh et al., 1999). From then on, CR-kpn with New Delhi metallo-β-lactamase (NDM) and *Klebsiella pneumoniae* carbapenemase (KPC) disseminated worldwide, which makes the treatment options limited to a few antibiotics such as tigecycline and polymyxins (Motsch et al., 2020). However, in a recent study, Van Duin et al. demonstrated that 46% of CR-KPN are also resistant to tigecycline to some extent, and as the last resort drug, polymyxins had a big safety concern for its nephrotoxicity and neurotoxicity (van Duin et al., 2015). Moreover, the emergence of carbapenemase-resistant hypervirulent *K. pneumoniae* (CR-hvKP) in recent years, which caused a higher mortality rate, has further exacerbated the dilemma of antibiotic therapy, triggering the need for alternative therapies (Lan et al., 2021).

Bacteriophages (phages) are bacterial viruses that specifically recognize, infect, and replicate within host bacteria. Phages have been considered therapeutic agents since the early 1920s as a result of their unique antibacterial ability (Wang et al., 2021). In addition, phages have the advantages of strong antibacterial ability and high quantity, as well as low toxic side effects to humans, and are considered to be the most promising drugs to replace traditional antibiotics. Some studies using mice as an animal model have shown that phages have promising therapeutic effects on pneumonia, liver abscesses, and burn infections caused by *K. pneumoniae* (Lin et al., 2014; Chadha et al., 2017; Anand et al., 2020). In addition, phage therapy has also been used in clinical practice to cure serious infections caused by MDR-KP. For example, in 2019, Wu Nannan et al. have reported the combination of phage and antibiotics against *K. pneumoniae* to cure a recurrent urinary tract infection caused by MDR-KP (Bao et al., 2020). In February 2019, a 62-year-old patient, with a prosthetic joint infection caused by *K. pneumoniae* KpH46, was successfully treated with phage KpH46Φ2 combined with antibiotics at the Mayo Clinic Infectious Disease Unit in Rochester, MN, USA (Cano et al., 2021). Although phage therapy has great potential for future applications, the specificity of phages to bacteria and the clearance of phages by the immune system are challenges for phage therapy. The discovery of new phages and evaluation of their antimicrobial capacity are one of the effective ways to overcome these challenges.

Here, we reported a lytic phage BUCT541 against *K. pneumoniae*. Not only the physiological characteristics of phage BUCT541 were determined but also the genetic background of BUT541 was revealed using bioinformatics tools. In addition, the ability of phage BUCT541 to treat *K. pneumoniae* infection was further evaluated in the *Galleria mellonella* larvae infection model and the mice infection model.

Materials and methods

Isolation and purification of BUCT541

Bacteriophage BUCT541 was isolated by using *K. pneumoniae* S-2007 as the host strain from sewage samples, which were collected from the Aviation General Hospital sewer system. The isolation method of BUCT541 was similar to the one described by Li et al. with slight variations (Li et al., 2021). In brief, untreated sewage samples were centrifuged to remove large impurities. Then, the samples were concentrated using a permeable membrane and PEG8000 for 3 h, and the concentrated solution was filtered through a 0.22-µm filter. Concentrated sewage samples (2 µL) were spotted on the lawn with *K. pneumoniae* S-2007 and cultured overnight at 37°C to obtain phage plaques of BUCT541. Plaques were picked up and co-cultured with *K. pneumoniae* S-2007 in LB medium for 8 h. The supernatant of the culture after centrifuging was filtered through a 0.22-µm filter and purified the phage BUCT541 by the double-layer plate method until a single morphology plaque was formed on the lawn with *K. pneumoniae* S-2007. And then, the phage BUCT541 suspension was further purified by discontinuous cesium chloride (CsCl) density gradient (ρ = 1.3, 1.5, and 1.7) and centrifuged at 30,000 × g for 2 h at 4°C. Finally, the banded phage particle was collected and dialyzed with PBS buffer (0.1 M, pH 7.4) (Uchiyama et al., 2011).

Electron micrograph of phage BUCT541

To visualize phages, the 30 µL of purified phages BUCT541 lysate was incubated with the carbon-coated copper grid for 10 min and stained with 2% uranyl acetate for 90 s and subsequently air dried. The morphology of the phages was
examined with a transmission electron microscope (JEM-1200EX, Japan) at 80 kV.

Multilocus sequence typing (MLST) and capsule type of bacteria

Thirty strains of MDR-KP were collected from the Aviation General Hospital. The lytic range of phage BUCT541 was determined by the double-layer plate method and spotting method. Some phages have been reported to have the ability to lyse different subtypes of the same bacteria (Zhang et al., 2021). To investigate whether phage BUCT541 can lyse different subtypes of K. pneumoniae, the MLST and capsule type of 30 strains of MDR-KP were identified. In brief, seven housekeeping genes (rpoB, gapA, mdh, pgi, phoE, infB, and tonB) and wzi gene of the 30 bacteria were subjected to PCR amplification. The amplified products were sent to the Beijing Ruibo Xingke Biotechnology Co., Ltd. for bidirectional sequencing. The sequencing results were analyzed by the MLST database (https://bigsdb.pasteur.fr/cgi-bin/bigsdb/bigsdb.pl?db=pubmlst_klebsiella_seqdef&l=1) for analysis. Primer sequences were shown in Supplementary Table S1.

Optimal multiplicity of infection of BUCT541

S-2007 was cultured to exponential phase and the number was counted. Around 100 µL of the mixture including BUCT541 and S-2007 with different MOIs (0.001, 0.01, 0.1, 1, 10, 100) were added to the 10 mL LB medium for overnight culture at 37°C with shaking (220 rpm). Then, the phage titers were determined after being cultured. The proportion with the highest phage titer was the optimal multiplicity of infection.

One-step growth curve assay of phage BUCT541

The mixture of BUCT541 and host S-2007 was incubated for 10 min at room temperature with optimal MOI. The supernatant was discarded after centrifugation at 4°C for 3 min at 12,000 ×g. The precipitate was resuspended with LB and centrifuged for 3 min at 4°C and 12,000 ×g, and then the above steps are repeated. The mixture after resuspension was added to 25 mL of LB liquid medium and cultured at 37°C for 150 min with shaking at 200 rpm. The titer of phage BUCT541 was detected at different time points. The above experiments were performed on ice. The titer of BUCT541 at different time points was detected by the double-layer plate method.

The stability determination of phage BUCT541

The method of phage BUCT541 stability determination is similar to that described by Ahmed R. Sofy et al. but with slight changes (Sofy et al., 2021). About 500 µL (3 × 10⁹ PFU/mL) of phage BUCT541 was incubated at 4, 37, 50, 60, and 70°C for 0.5, 1, 1.5, and 2 h, respectively. The titer of phage BUCT541 was detected by the double-layer plate method with different incubation times. Similarly, 500 µL (5 × 10⁹ PFU/mL) of phage BUCT541 was incubated for 2, 4, and 6 h at pH = 3, 5, 7, 9, and 11, respectively. The titer of phage BUCT541 was detected with different incubation times.

Genome sequence and bioinformatics analysis of phage BUCT541

Extract the phage genome using the classical K/SDS method and the phage DNA samples were sent to Annoroad company for next-generation sequencing (NGS). The raw sequenced reads were assessed for quality using FastQC v.0.11.5 and filtered for low-quality reads and adapter regions using Trimmomatic v.0.36 (Madaha et al., 2020). The high-quality reads were spliced using SPAdes v3.13.0 (Zoledowska et al., 2018). Spliced data were removed from head and tail duplicate regions by SnapGene. Genome sequence similarity was aligned using BLASTn (https://blast.ncbi.nlm.nih.gov/Blast.cgi?PROGRAM=blastn&PAGE_TYPE=BlastSearch&LINK_LOC=blasthome). Use the online website to predict RAST open reading frames (ORFs) (https://rast.nmpdr.org/rast.cgi) and rectify the predictions through the NCBI database. The molecular weight of ORFs encoded proteins was determined using the ExPaSY ProtParam online website (https://web.expasy.org/protparam/) (Karunaratna et al., 2020). Gene function maps were created using a lab-built program and retouched with the software Inkscape 0.92.3.0. The tRNAscan-SE v.2.0 was used to predict tRNA (http://lowelab.ucsc.edu/cgi-bin/trNAscan-SE2.cgi) (Alam and Rao, 2008). ResFinder (https://cge.cbs.dtu.dk/services/ResFinder/) and VirulenceFinder (https://cge.cbs.dtu.dk/services/VirulenceFinder/) were used to detect drug resistance genes and virulence genes, respectively (Joensen et al., 2014; Bortolaia et al., 2020). Construction of a complete genome phylogenetic tree based on the whole genome sequence of BUCT541 using the genome-BLAST distance phylogenetic approach in virus classification and VICTOR (https://ggdc.
Assessment of the efficacy of BUCT541 against *K. pneumoniae* S-2007 in vitro

The *K. pneumoniae* S-2007 was cultured to OD$_{600}$ of about 0.25 at 37°C and 120 rpm. The 5 mL of phage BUCT541 with different titers (10$^6$, 10$^7$, 10$^8$ PFU/mL) were mixed with 25 mL S-2007, respectively. The mixture of different MOIs (0.01, 0.1, 1, 10) was continued to cultivate at 37°C, 120 rpm for 8 h. For the control group, only 5 mL LB liquid medium and 25 mL S-2007 were mixed and cultured for 8 h at 37°C, 120 rpm. And the concentration of *K. pneumoniae* S-2007 during the cultivation was responded by OD$_{600}$. OD$_{600}$ was measured by nanodrop (Thermo scientific).

Data availability

All data were analyzed using the GraphPad Prism 8.0.1 and expressed as means and standard deviation values. Student's test (t test) analysis was used in Figures 2A, 7C. The complete genome sequence of bacteriophage BUCT541 has been deposited in GenBank under the accession number MZ836210.1

Results

Morphology and host range of phage BUCT541

BUCT541 forms clear, translucent, and regular plaques on a lawn of *K. pneumoniae* S-2007 with clear haloes distributed around the plaque center (Figure 1A). The electron micrographs show that the head diameter of BUCT541 was 57.013 ± 1.302 nm and the tail length was 147.263 ± 2.349 nm (Figure 1B). Based on the morphological classification, BUCT541 was considered to belong to the *Siphoviridae* family. Thirty strains of *K. pneumoniae* were collected from the Aviation General Hospital, and seven of them could be lysed by BUCT541.
Multilocus sequence typing and capsular type identification of bacteria

Seven alleles of gapA, infB, mdh, pgi, phoE, rpoB and tonB were arranged in that order and analyzed using the multilocus sequence typing scheme that was developed for K. pneumoniae. According to the analysis of the MLST Database, the capsular type and multi-locus sequence type of host bacteria of phage BUCT541 belong to K1 and sequence type 23 (ST23), respectively. K1-ST23 K. pneumoniae is one of the hypervirulent K. pneumoniae (hv-KP) in clinical practice (Nakamura et al., 2021). The capsular type and multi-locus sequence type of other K. pneumoniae were shown in Table 1.

Physiological characterization of phage BUCT541

When the MOI was 0.01, the titer of phage BUCT541 in the culture was significantly higher than other MOIs, indicating that the MOI of 0.01 was most suitable for the growth of phage BUCT541 (Figure 2A). The one-step growth curve showed that the latent and lytic periods of BUCT541 were about 30 min and 50 min, respectively (Figure 2B). The titer of BUCT541 was highest at pH = 7 and decreased significantly at pH = 9 and pH = 11 with the same incubation time. In the same buffer, the titer of BUCT541 decreased at the longer incubation times, except at pH = 7 where the titer was essentially constant at all incubation times tested (Figure 2C). We also found that the titer of BUCT541 was significantly less in the acidic buffer than that in the alkaline buffer, indicating that BUCT541 was more stable in the acidic environments. The titer of BUCT541 was relatively stable at 4 to 60°C but rapidly decreased at 70°C (Figure 2D), indicating BUCT541 had good thermal stability.

Characteristics and annotations of the complete genome of phage BUCT541

The complete genome sequence of phage BUCT541 has been submitted to NCBI (GenBank: MZ836210.1). The BUCT541 genome is a double-stranded linear 46,100 bp long DNA molecule with 48% GC content. A total of 81 open reading frames (ORFs) are annotated (Table 2) and 21 of them encode proteins with functions associated with phage lysis, regulation, packaging, structure, and replication (Figure 3). The other ORFs are annotated as encoding hypothetical proteins. The genome sequence alignment of phage BUCT541 with the genome sequences of other Klebsiella phages showed that BUCT541 shared the highest cover (84%) and identity (97.9%) with Klebsiella phage vB_KpnS_ZX4 (GenBank: NC_054654.1) (Figure 4A), followed by Klebsiella virus KpV2811 (GenBank: NC_054653.1) (Figure 4B), Klebsiella phage YX3973 (GenBank: NC_054652.1) (Figure 4C), and Klebsiella phage ZCKP8 (GenBank: MZ440881.1) (Figure 4D), which shared 71%, 64%, and 60% identity, respectively. In addition, the complete genome phylogenetic tree of BUCT541 and other phages showed that BUCT541 also shared a close evolutionary relationship with Vibrio phage pYD38-A (GenBank: JF974312.1) and Aeromonas phage pIS4-A (GenBank: NC_042037.1) (Figure 5A).
TABLE 1  Detail information of bacteria of host range tested.

| Species     | Strain | ST type | Capsular type | Origin                        | Sensitivity |
|-------------|--------|---------|---------------|-------------------------------|-------------|
| K. pneumoniae | S-2007 | ST23    | K1            | Aviation General Hospital     | +           |
| K. pneumoniae | 081    | ST23    | K1            | Aviation General Hospital     | +           |
| K. pneumoniae | 064    | ST23    | K1            | Aviation General Hospital     | +           |
| K. pneumoniae | K7     | ST23    | K1            | Aviation General Hospital     | +           |
| K. pneumoniae | 2,752  | ST23    | K1            | Aviation General Hospital     | +           |
| K. pneumoniae | 2,755  | ST23    | K1            | Aviation General Hospital     | +           |
| K. pneumoniae | 2,024  | ST23    | K1            | Aviation General Hospital     | +           |
| K. pneumoniae | 2,011  | N/A     | K25           | Aviation General Hospital     | –           |
| K. pneumoniae | 2,012  | ST11    | K25           | Aviation General Hospital     | –           |
| K. pneumoniae | 2,013  | ST15    | K19           | Aviation General Hospital     | –           |
| K. pneumoniae | 2,014  | N/A     | K47           | Aviation General Hospital     | –           |
| K. pneumoniae | 2,015  | ST11    | K47           | Aviation General Hospital     | –           |
| K. pneumoniae | 2,086  | ST11    | K64           | Aviation General Hospital     | –           |
| K. pneumoniae | 2,017  | ST15    | K19           | Aviation General Hospital     | –           |
| K. pneumoniae | 2,018  | ST11    | N/A           | Aviation General Hospital     | –           |
| K. pneumoniae | 2,019  | N/A     | K47           | Aviation General Hospital     | –           |
| K. pneumoniae | 2,020  | N/A     | K47           | Aviation General Hospital     | –           |
| K. pneumoniae | 2,068  | ST15    | K19           | Aviation General Hospital     | –           |
| K. pneumoniae | 2,022  | ST11    | K47           | Aviation General Hospital     | –           |
| K. pneumoniae | 2,002  | ST15    | K19           | Aviation General Hospital     | –           |
| K. pneumoniae | 2,003  | ST15    | K19           | Aviation General Hospital     | –           |
| K. pneumoniae | 2,004  | ST11    | K47           | Aviation General Hospital     | –           |
| K. pneumoniae | 2,005  | ST11    | K25           | Aviation General Hospital     | –           |
| K. pneumoniae | 2,006  | ST11    | K47           | Aviation General Hospital     | –           |
| K. pneumoniae | 2,008  | ST11    | K64           | Aviation General Hospital     | –           |
| K. pneumoniae | 2,009  | ST11    | K64           | Aviation General Hospital     | –           |
| K. pneumoniae | 2,021  | N/A     | K64           | Aviation General Hospital     | –           |
| K. pneumoniae | 2,022  | ST11    | K47           | Aviation General Hospital     | –           |
| K. pneumoniae | 2,026  | ST11    | K64           | Aviation General Hospital     | –           |
| K. pneumoniae | 2,027  | ST15    | K19           | Aviation General Hospital     | –           |

*“+” susceptible; “–” resistance; “N/A” mutation.

Replication-, transcription-, regulation-, and packaging-related genes of phage BUCT541

The annotations of the BUCT541 genome sequence indicate that 13 ORFs had functions associated with the replication, translation, and regulation of BUCT541. ORF12, ORF13, and ORF15 are annotated as primase helicase, DEAD/DEAH box helicase, and exodeoxyribonuclease 8, respectively. DEAD-box helicases are a large family of conserved RNA-binding proteins that belong to the broader group of cellular DExD/H helicases. Cellular RNA helicases, including DEAD/DEAH box helicases, have been shown to play roles in recognizing exogenous genes and regulating viral infections (Taschuk and Cherry, 2020). Exodeoxyribonuclease is involved in the RecE recombination pathway by catalyzing the degradation of double-stranded DNA progressively in the 5’ to 3’ direction, releasing 5’-phosphomonomonucleotides (Murphy, 2012). ORF16 is annotated as an ERF superfamily protein. ERF superfamily proteins have effective recombinase activity and play important roles in genetic recombination engineering (Ricaurte et al., 2018). ORF17 and ORF81 are both annotated as homing endonucleases, which are site-specific endonucleases that initiate homing, a non-reciprocal transfer of its own gene into a new allele that lacks this gene (Wilson and Edgell, 2009). However, the phage T4 endonuclease SegD, which is similar to group I intron endonucleases, did not initiate homing of its own gene or genetic recombination between phages in its site inserted into the rII locus (Sokolov et al., 2018). ORF18 is annotated as a single-strand binding protein. Single-stranded binding proteins
bind with high affinity and in a cooperative manner to single-stranded DNA but do not bind well to double-stranded DNA. After binding to single-stranded DNA, these proteins destabilize helical duplexes, thereby allowing DNA polymerases to access their substrate more easily. Single-stranded binding proteins play an important role in the replication of DNA. ORF33, ORF34, and ORF35 are annotated as tRNA-Ser-GCT, tRNA-Arg-TCT, and tRNA-Met-CAT, respectively, implying that large amounts of serine, arginine, and methionine may be required during the lifecycle of BUCT541. ORF46, ORF57, and ORF80 are annotated as putative C-specific methylase, transcription factor, and large terminase, respectively. The terminase large subunit acts as an ATP-driven molecular motor, which is necessary for viral DNA translocation into empty capsids, and as an endonuclease that cuts the viral genome to initiate and end packaging reactions (Leffers and Rao, 2000; Rao and Mitchell, 2001). The phylogenetic tree analysis based on the terminase large subunits constructed by the Neighbor-Joining Algorithm (NJ) method showed that the BUCT541 terminase large subunit shared the highest identity with the terminase large subunits of a Siphoviridae sp. virus (GenBank: DAZ46203.1) (Figure 5B).

Host cell lysis- and structure-related genes of phage BUCT541

ORF69 is annotated as a lysozyme in the BUCT541 genome. The PSI-BLAST (Position-Specific Iterated BLAST) alignment of the BUCT541 lysozyme amino acid sequence (GenBank: UAW06880.1) with the lysozyme amino acid sequences of closely related viruses showed that the BUCT541 lysozyme sequence shared high coverage (100%) and identity (98.61%) with the Klebsiella virus KpV2811 lysozyme sequence (GenBank: YP_010054471.1). ORF19 and ORF31 are annotated as putative tail fiber protein and major tail protein, respectively. Alignment of the BUCT541 tail fiber protein sequence (GenBank: UAW06833.1) with the tail fiber protein sequences of closely related viruses showed that the BUCT541 tail fiber protein sequence shared high cover (100%; E-value 0.0) and identity (95.96%) with the Klebsiella phage YX3973 tail fiber protein sequence.
| ORF | Strand | Start | Stop | Length (AA) | Putative function | Best-match BLASTp result | Query cover (%) | E-values | Identity (%) | Accession | MW (kDa) |
|-----|--------|-------|------|-------------|------------------|------------------------|----------------|---------|-------------|-----------|----------|
| ORF1 | -      | 489   | 73   | 138         | Hypothetical protein | *Salmonella enterica* | 100            | 2e-91    | 99.28       | WP_194549441.1 | 15.5     |
| ORF2 | -      | 785   | 591  | 64          | Hypothetical protein | *Klebsiella phage YX3973* | 100            | 2e-37    | 95.31       | YP_010054373.1 | 7.1      |
| ORF3 | -      | 943   | 785  | 52          | Hypothetical protein | *Siphoviridae* | 100            | 7e-30    | 98.08       | DAE56162.1 | 6.1      |
| ORF4 | -      | 1,919 | 1,035 | 294         | Hypothetical protein | *Klebsiella phage vB_Kpns_ZX4* | 70             | 8e-110   | 77.78       | YP_010054560.1 | 32.1     |
| ORF5 | -      | 2,204 | 1,926 | 92          | Hypothetical protein | *Klebsiella virus KpV2811* | 100            | 1e-58    | 100         | YP_010054492.1 | 10.5     |
| ORF6 | -      | 2,405 | 2,220 | 61          | Hypothetical protein | *Siphoviridae* | 100            | 5e-37    | 100         | DAF31840.1 | 6.7      |
| ORF7 | -      | 2,617 | 2,498 | 69          | Hypothetical protein | Not hit | - | - | - | - | 7.9 |
| ORF8 | +      | 2,679 | 3,014 | 111         | Hypothetical protein | *Siphoviridae* | 100            | 1e-49    | 76.58       | DAE56151.1 | 12.5     |
| ORF9 | +      | 3,103 | 3,381 | 92          | Hypothetical protein | *Siphoviridae* | 100            | 5e-60    | 95.65       | DAE56150.1 | 10.5     |
| ORF10| +     | 3,381 | 5,030 | 549         | Hypothetical protein | *Siphoviridae* | 100            | 0.0      | 97.81       | DAE56149.1 | 61.2     |
| ORF11| +     | 5,027 | 5,383 | 118         | Hypothetical protein | Not hit | - | - | - | - | 13.4 |
| ORF12| -     | 6,290 | 5,397 | 297         | TPA: MAG TPA: primase helicase | *Siphoviridae* | 100            | 0.0      | 95.62       | DAF74631.1 | 33.5     |
| ORF13| +     | 6,365 | 8,275 | 636         | DEAD/DEAH box helicase family protein | *Klebsiella pneumoniae* | 100            | 0.0      | 98.27       | WP_142483293.1 | 72.3     |
| ORF14| +     | 8,286 | 8,702 | 138         | Hypothetical protein | *Klebsiella phage BUCT610* | 100            | 2e-96    | 96.38       | QWX10336.1 | 15.7     |
| ORF15| +     | 8,747 | 9,685 | 312         | TPA: MAG TPA: Exodeoxyribonuclease 8 | *Siphoviridae* | 100            | 0.0      | 96.79       | DAN88330.1 | 35.6     |
| ORF16| +     | 9,709 | 10,371| 220         | TPA: MAG TPA: ERF superfamily protein | *Siphoviridae* | 100            | 4e-160   | 100         | DAE85886.1 | 24.0     |
| ORF17| +     | 10,452| 10,952| 166         | TPA: MAG TPA: homing endonuclease | *Siphoviridae* | 100            | 5e-118   | 100         | DAE85905.1 | 18.7     |
| ORF18| +     | 10,952| 11,455| 167         | TPA: MAG TPA: Single strand binding protein | *Siphoviridae* | 100            | 4e-111   | 95.21       | DAE85903.1 | 18.5     |
| ORF19| -     | 13,937| 11,484| 817         | Hypothetical protein | *Klebsiella virus KpV2811* | 100            | 0.0      | 98.04       | YP_010054425.1 | 86.3     |
| ORF20| -     | 16,432| 13,976| 818         | Hypothetical protein | *Klebsiella phage vB_Kpns_ZX4* | 100            | 0.0      | 99.76       | YP_010054541.1 | 89.6     |
| ORF21| -     | 16,862| 16,404| 152         | Hypothetical protein | *Klebsiella phage vB_Kpns_ZX4* | 100            | 1e-109   | 99.34       | YP_010054441.1 | 17.5     |
| ORF22| -     | 17,295| 16,825| 156         | Hypothetical protein | *Klebsiella phage YX3973* | 100            | 4e-110   | 99.36       | YP_010054357.1 | 17.9     |
| ORF23| -     | 17,765| 17,295| 156         | Hypothetical protein | *Klebsiella phage YX3973* | 100            | 1e-111   | 100         | YP_010054356.1 | 17.8     |
| ORF24| -     | 21,046| 17,765| 1,093       | Tail length tape-measure protein 1 | *Klebsiella phage vB_Kpns_ZX4* | 100            | 0.0      | 99.82       | YP_010054441.1 | 114.3    |
| ORF25| -     | 21,753| 21,046| 235         | Hypothetical protein | *Siphoviridae* | 100            | 1e-172   | 99.15       | DAF78471.1 | 30.5     |
| ORF26| +     | 21,850| 21,978| 42          | Hypothetical protein | *Siphoviridae* | 100            | 3e-20    | 100         | YP_010054391.1 | 4.7      |
| ORF27| +     | 22,133| 22,133| 50          | Hypothetical protein | *Siphoviridae* | 100            | 2e-27    | 100         | YP_010054381.1 | 5.6      |
| ORF28| +     | 22,450| 22,133| 105         | Hypothetical protein | *Klebsiella phage YX3973* | 100            | 9e-73    | 100         | YP_010054353.1 | 12.1     |
| ORF29| +     | 22,621| 22,621| 50          | Hypothetical protein | *Siphoviridae* | 100            | 3e-26    | 98.00       | DAF31827.1 | 5.6      |
| ORF30| +     | 22,818| 22,818| 65          | Hypothetical protein | *Siphoviridae* | 100            | 1e-38    | 100         | DAF31826.1 | 7.9      |
| ORF31| -     | 23,594| 22,839| 251         | TPA: MAG TPA: major tail protein | *Siphoviridae* | 100            | 3e-172   | 95.22       | DAE85900.1 | 26.8     |
| ORF   | Strand | Start  | Stop   | Length (AA) | Putative function                     | Best-match BLASTp result                      | Query cover (%) | E-values | Identity (%) | Accession        | MW (kDa) |
|-------|--------|--------|--------|------------|---------------------------------------|-----------------------------------------------|-----------------|----------|--------------|-----------------|----------|
| ORF32 | +      | 23,904 | 24,038 | 44         | Hypothetical protein                   | Enterobacter phage Tyriorn                     | 90              | 4e-14    | 87.50        | YP_009447826.1 | 4.8      |
| ORF33 | +      | 24,081 | 24,165 | 8          | tRNA-Ser-GCT                           | Enterobacter phage Tyriorn                     | 90              | 4e-14    | 87.50        | YP_009447826.1 | 4.8      |
| ORF34 | +      | 24,175 | 24,248 | 74         | tRNA-Arg-TCT                           | Enterobacter phage Tyriorn                     | 90              | 4e-14    | 87.50        | YP_009447826.1 | 4.8      |
| ORF35 | +      | 24,255 | 24,328 | 74         | tRNA-Met-CAT                           | Enterobacter phage Tyriorn                     | 90              | 4e-14    | 87.50        | YP_009447826.1 | 4.8      |
| ORF36 | +      | 24,347 | 24,557 | 61         | Hypothetical protein                   | Vibrio phage pYD3-A                            | 90              | 4e-14    | 87.50        | YP_009447826.1 | 4.8      |
| ORF37 | +      | 24,547 | 24,585 | 43         | Hypothetical protein                   | Vibrio phage pYD3-A                            | 90              | 4e-14    | 87.50        | YP_009447826.1 | 4.8      |
| ORF38 | +      | 24,735 | 24,898 | 164        | Hypothetical protein                   | Vibrio phage pYD3-A                            | 90              | 4e-14    | 87.50        | YP_009447826.1 | 4.8      |
| ORF39 | +      | 24,998 | 25,178 | 40         | Hypothetical protein                   | Vibrio phage pYD3-A                            | 90              | 4e-14    | 87.50        | YP_009447826.1 | 4.8      |
| ORF40 | +      | 25,175 | 25,377 | 202        | Hypothetical protein                   | Siphoviridae sp.                               | 90              | 4e-14    | 87.50        | YP_009447826.1 | 4.8      |
| ORF41 | +      | 25,347 | 25,449 | 102        | Hypothetical protein                   | Siphoviridae sp.                               | 90              | 4e-14    | 87.50        | YP_009447826.1 | 4.8      |
| ORF42 | +      | 25,547 | 25,651 | 104        | Hypothetical protein                   | Siphoviridae sp.                               | 90              | 4e-14    | 87.50        | YP_009447826.1 | 4.8      |
| ORF43 | +      | 25,735 | 25,898 | 164        | Hypothetical protein                   | Siphoviridae sp.                               | 90              | 4e-14    | 87.50        | YP_009447826.1 | 4.8      |
| ORF44 | +      | 25,998 | 26,178 | 180        | Hypothetical protein                   | Siphoviridae sp.                               | 90              | 4e-14    | 87.50        | YP_009447826.1 | 4.8      |
| ORF45 | +      | 26,175 | 26,377 | 202        | Hypothetical protein                   | Siphoviridae sp.                               | 90              | 4e-14    | 87.50        | YP_009447826.1 | 4.8      |
| ORF46 | +      | 26,347 | 26,449 | 102        | Hypothetical protein                   | Siphoviridae sp.                               | 90              | 4e-14    | 87.50        | YP_009447826.1 | 4.8      |
| ORF47 | +      | 26,547 | 26,651 | 104        | Hypothetical protein                   | Siphoviridae sp.                               | 90              | 4e-14    | 87.50        | YP_009447826.1 | 4.8      |
| ORF48 | +      | 26,735 | 26,898 | 164        | Hypothetical protein                   | Siphoviridae sp.                               | 90              | 4e-14    | 87.50        | YP_009447826.1 | 4.8      |
| ORF49 | +      | 26,998 | 27,178 | 180        | Hypothetical protein                   | Siphoviridae sp.                               | 90              | 4e-14    | 87.50        | YP_009447826.1 | 4.8      |
| ORF50 | +      | 27,175 | 27,377 | 202        | Hypothetical protein                   | Siphoviridae sp.                               | 90              | 4e-14    | 87.50        | YP_009447826.1 | 4.8      |
| ORF51 | +      | 27,347 | 27,449 | 102        | Hypothetical protein                   | Siphoviridae sp.                               | 90              | 4e-14    | 87.50        | YP_009447826.1 | 4.8      |
| ORF52 | +      | 27,547 | 27,651 | 104        | Hypothetical protein                   | Siphoviridae sp.                               | 90              | 4e-14    | 87.50        | YP_009447826.1 | 4.8      |
| ORF53 | +      | 27,735 | 27,898 | 164        | Hypothetical protein                   | Siphoviridae sp.                               | 90              | 4e-14    | 87.50        | YP_009447826.1 | 4.8      |
| ORF54 | +      | 27,998 | 28,178 | 180        | Hypothetical protein                   | Siphoviridae sp.                               | 90              | 4e-14    | 87.50        | YP_009447826.1 | 4.8      |
| ORF55 | +      | 28,175 | 28,377 | 202        | Hypothetical protein                   | Siphoviridae sp.                               | 90              | 4e-14    | 87.50        | YP_009447826.1 | 4.8      |
| ORF56 | +      | 28,347 | 28,449 | 102        | Hypothetical protein                   | Siphoviridae sp.                               | 90              | 4e-14    | 87.50        | YP_009447826.1 | 4.8      |
| ORF57 | +      | 28,547 | 28,651 | 104        | Hypothetical protein                   | Siphoviridae sp.                               | 90              | 4e-14    | 87.50        | YP_009447826.1 | 4.8      |
| ORF58 | +      | 28,735 | 28,898 | 164        | Hypothetical protein                   | Siphoviridae sp.                               | 90              | 4e-14    | 87.50        | YP_009447826.1 | 4.8      |
| ORF59 | +      | 28,998 | 29,178 | 180        | Hypothetical protein                   | Siphoviridae sp.                               | 90              | 4e-14    | 87.50        | YP_009447826.1 | 4.8      |
| ORF60 | +      | 30,175 | 30,377 | 202        | Hypothetical protein                   | Siphoviridae sp.                               | 90              | 4e-14    | 87.50        | YP_009447826.1 | 4.8      |
| ORF61 | +      | 30,347 | 30,449 | 102        | Hypothetical protein                   | Siphoviridae sp.                               | 90              | 4e-14    | 87.50        | YP_009447826.1 | 4.8      |
| ORF62 | +      | 30,547 | 30,651 | 104        | Hypothetical protein                   | Siphoviridae sp.                               | 90              | 4e-14    | 87.50        | YP_009447826.1 | 4.8      |
| ORF   | Strand | Start  | Stop   | Length (AA) | Putative function               | Best-match BLASTp result                  | Query cover (%) | E-values   | Identity (%) | Accession         | MW (kDa) |
|-------|--------|--------|--------|-------------|---------------------------------|-------------------------------------------|-----------------|-----------|--------------|------------------|----------|
| ORF63 | +      | 36,555 | 37,025 | 156         | Hypothetical protein             | Klebsiella phage vB_KpnS_X4               | 100             | 4e-108   | 98.72        | YP_010054507.1  | 17.6     |
| ORF64 | +      | 37,025 | 37,249 | 74          | Hypothetical protein             | *Siphoviridae* sp. ctbqG28                | 100             | 3e-45    | 97.30        | DAD75123.1      | 8.0      |
| ORF65 | +      | 37,246 | 37,374 | 42          | Hypothetical protein             | *Siphoviridae* sp. ctbqG28                | 100             | 5e-22    | 100.00       | DAD75124.1      | 4.8      |
| ORF66 | −      | 37,540 | 37,421 | 130         | Hypothetical protein             | Klebsiella phage vB_KpnS_X4               | 100             | 4e-20    | 97.44        | DAD75125.1      | 4.7      |
| ORF67 | −      | 37,904 | 37,524 | 126         | Hypothetical protein             | *Siphoviridae* sp. ctbqG28                | 100             | 2e-84    | 99.21        | YP_010054505.1  | 14.2     |
| ORF68 | −      | 38,124 | 38,911 | 77          | Hypothetical protein             | *Siphoviridae* sp. ctbqG28                | 100             | 2e-46    | 94.81        | YP_008126191.1  | 8.7      |
| ORF69 | −      | 38,555 | 38,121 | 144         | TPA: MAG TPA: Lysozyme           | *Siphoviridae* sp. ctbqG28                | 100             | 2e-103   | 100.00       | DAD75107.1      | 15.7     |
| ORF70 | +      | 38,654 | 38,944 | 96          | Hypothetical protein             | Klebsiella phage YX3973                   | 100             | 1e-60    | 100.00       | YP_010054387.1  | 9.9      |
| ORF71 | +      | 38,944 | 39,075 | 43          | Hypothetical protein             | Klebsiella phage vB_KpnS_X4               | 100             | 5e-23    | 100.00       | YP_010054501.1  | 5.0      |
| ORF72 | +      | 39,072 | 39,920 | 268         | Hypothetical protein             | Klebsiella phage vB_KpnS_X4               | 100             | 2e-139   | 73.85        | DAO12191.1      | 31.4     |
| ORF73 | −      | 40,498 | 40,004 | 314         | Hypothetical protein             | Klebsiella phage vB_KpnS_X4               | 100             | 0.0      | 99.04        | YP_010054498.1  | 35.5     |
| ORF74 | −      | 42,365 | 40,929 | 478         | Hypothetical protein             | Klebsiella phage vB_KpnS_X4               | 100             | 0.0      | 97.72        | YP_010054497.1  | 53.6     |
| ORF75 | +      | 42,672 | 42,878 | 86          | Hypothetical protein             | Klebsiella pneumoniae                    | 100             | 3e-38    | 98.53        | WP_116431175.1  | 7.3      |
| ORF76 | +      | 42,880 | 42,323 | 123         | TPA: MAG TPA: MerR family regulatory protein | Klebsiella pneumoniae                    | 100             | 3e-86    | 99.19        | DAF31849.1      | 13.8     |
| ORF77 | −      | 43,502 | 43,323 | 59          | Hypothetical protein             | *Siphoviridae* sp.                       | 100             | 2e-32    | 98.31        | DAF31848.1      | 6.8      |
| ORF78 | −      | 43,738 | 43,499 | 79          | Hypothetical protein             | Klebsiella phage vB_KpnS_X4               | 100             | 6e-50    | 100.00       | YP_010054495.1  | 9.2      |
| ORF79 | +      | 43,829 | 44,119 | 96          | Hypothetical protein             | Klebsiella phage YX3973                   | 100             | 1e-62    | 100.00       | YP_010054377.1  | 10.6     |
| ORF80 | −      | 45,564 | 44,140 | 174         | TPA: MAG TPA: large terminase    | *Siphoviridae* sp.                       | 100             | 0.0      | 100.00       | DAZ46203.1      | 54.2     |
| ORF81 | −      | 46,069 | 45,557 | 170         | Homing endonuclease              | Klebsiella phage YX3973                   | 100             | 1e-122   | 100.00       | YP_010054375.1  | 19.3     |
Genomic map of bacteriophage BUCT541 and its genetic characteristics. Open reading frames (ORFs) are represented in different colors according to their functional categories. ORF39, ORF52, and ORF53 are annotated as minor capsid protein, coat protein, and capsid stabilizing protein, respectively. The main function of capsid proteins is to protect the stability of DNA (Plano et al., 2021). Because capsid protein sequences are highly conserved, they have been used as a basis for studies into the evolutionary history of phages (Buttimer et al., 2018; Shi et al., 2020). The phylogenetic tree analysis based on the capsid protein constructed by the NJ method showed that the BUCT541 capsid protein had the closest relationship with the Siphoviridae sp. minor capsid protein (GenBank: DAE85897.1) (Figure 5C).

Evaluation of the efficacy of phage BUCT541 against *K. pneumoniae* S-2007 in vitro

During the first hour, the concentration of *K. pneumoniae* S-2007 of the cultures with different MOIs (1, 0.1, 0.01) increased and the increase was basically the same with the control group. However, it decreased sharply at 1 to 2 h. It is noteworthy that with MOI = 10, the concentration of *K. pneumoniae* S-2007 of the cultures was basically unchanged during the first 2h. After 2h, the concentration of *K. pneumoniae* S-2007 of the cultures in the different MOIs groups increased again, but the...
Evaluation of the efficacy of phage BUCT541 to treat *K. pneumoniae* S-2007 *in vivo*

Survival rates of *K. pneumoniae* S-2007-infected *G. mellonella* larvae were 17%, 83.33%, and 10% within 48 h when the MOIs of BUCT541 were 10, 1, and 0.1, respectively (Figure 7A). Almost all of the larvae in the positive control group died within 48 h, and all the larvae in the negative group survived. The survival rates of the BALB/c mice were 100% and 50% within 7 days when the MOIs of BUCT541 were 10 and 1, respectively (Figure 7B). All the mice in the positive control group died within 4 days, and all the mice in the negative group survived. After 30 h treatment with phage BUCT541, the *K. pneumoniae* S-2007 amount in the lungs of positive control mice was as high as $10^9$ CFU/mL, while the amount of S-2007 was lower than $10^4$ CFU/mL when mice were treated with high titers (MOI = 10) of phage BUCT541. The results showed that phage BUCT541 significantly inhibited the growth of *K. pneumoniae* S-2007 in the lungs of mice (Figure 7C). And the histopathologic examination showed that such high titers of BUCT541 significantly reduced the lesions in the mouse lungs and did not affect the normal life activities of the mice (Figures 8A–D). We also noted that infection with BUCT541 alone sometimes caused a mild inflammatory response in the mouse lungs, but this side effect did not pose a threat to the normal activity of the mice (Figure 8C).
Discussion

Here, we characterized phage BUCT541 and showed that it could lyse MDR-KP K1-ST23, which belonged to the clinically prevalent hvKp. In recent years, the epidemic hvKp K1-ST23 is a big threat as the causative agent in multiple diseases, especially in pyogenic liver abscesses (Chung et al., 2012; Harada et al., 2019). By acquiring mobile elements that carry resistance determinants, hvKp strains have become increasingly resistant to antimicrobial agents (Russo and Marr, 2019). Moreover, the emergence of CR-hvKP caused a higher mortality rate for its characteristic of high virulence and carbapenem resistance, which has further exacerbated the dilemma of antibiotic therapy, triggering the need for alternative therapies (Lan et al., 2021). Phages are considered to be one of the most promising alternative drugs to replace or supplement antibiotic therapy. Therefore, phage BUCT541 with the ability to lyse hvKp K1-ST23 will be a promising treatment option for curing hvKp infection.

BUCT541 formed clearly visible plaques with large diameters on a bacterial lawn of K. pneumoniae S-2007.
BUCT541 belongs to the *Siphoviridae* family (Ackermann, 2009), as was indicated by electron microscopic and bioinformatics analysis. Interestingly, the electron micrographs showed that the tail terminal of BUCT541 has a special convex structure. Because the phage tail structure is associated with phage adsorption to hosts (Ackermann, 2009), we speculated that the convex structure may be related to the rapid adsorption and high burst of phage BUCT541, and also may be associated with the phage depolymerase. Phage depolymerases are generally located above the tail fiber and tail spike proteins, and changes in the structure of the phage tail fibronectin have been shown to significantly affect the adsorption rate of the phage (Drulis-Kawa et al., 2015; Roach and Donovan, 2015). It has been shown that changes in the structure of the phage tail fibronectin can significantly affect the adsorption rate of the phage (Heller and Braun, 1979). This speculation is consistent with our findings that haloes were distributed around the lysis center of phage BUCT541 and that ORF19 in the BUCT541 genome is annotated as a tail fiber protein. The thermal and pH stability showed that phage BUCT541 is similar to *Klebsiella*.
PHage vB_KpnP_IME279 (Heller and Braun, 1979), which is tolerant to a broad pH range (3–11) and has good thermal stability (4–60°C). Extreme pH conditions affect phage activity by causing irreversible precipitation and coagulation. We found that BUCT541 has good pH and temperature tolerance, which facilitates the storage of BUCT541 and makes it a potential biocontrol agent.

The biological characteristics and safety of phages for phage therapy can be predicted by bioinformatics analysis. The phylogenetic tree based on the complete genomes of BUCT541 and related phages showed that BUCT541 shared the closest evolutionary relationship with the K. pneumoniae phage vB_KpnS_ZX4 (GenBank: NC_054654.1), and also had a close evolutionary relationship with Vibrio phage
FIGURE 6
Growth curves of K. pneumoniae S-2007 infected with BUCT541 at different MOIs.

FIGURE 7
Evaluation of the effect of phage BUCT541 against K. pneumoniae S-2007 in vivo. (A) Survival curves of G. mellonella larvae after treatment with phage BUCT541 at different MOIs or PBS. (B) Survival curves of mice treated with phage BUCT541 at different MOIs or PBS. (C) The amount of K. pneumoniae S-2007 in the lungs of mice after 30 h treatment with different MOIs phage BUCT541. Data are shown as the mean ± SD, ****P < 0.0001, ***P < 0.001, and **P < 0.01, indicate a significant difference compared to the control group.

pYD38-A (GenBank: JF974312.1) and Aeromonas phage pIS4-A (GenBank: NC_042037.1). These results demonstrate the genetic diversity of BUCT541 and provide further information for exploring the genomic evolution of phages (Hatfull and Hendrix, 2011; Reyes and Vives, 2020). ORF 69 of phage BUCT541 was annotated as lysozyme which has a conserved structure and function (Baase et al., 2010). Phage lysozymes have been developed for the detection and prevention of diseases in humans and agriculture (Young, 2014). Notably, ORF33, ORF34, and ORF35 in the BUCT541 genome are annotated as tRNA-Ser-GCT, tRNA-Arg-TCT, and tRNA-Met-CAT, respectively, which is unusual because tRNAs are not commonly found in the genomes of other K. pneumoniae phages. We speculate that the replication of BUCT541 may require large amounts of serine (Ser), arginine (Arg), and methionine (Met), which are not efficiently transported by the host, and that BUCT541 evolved the tRNA genes to accelerate the synthesis of Ser, Arg, and Met in the host. Notably, no virulence or drug-resistant genes were annotated in the complete genome of phage BUCT541, suggesting that it may be safe to use BUCT541 as a therapeutic or biocontrol agent; however, the large number of hypothetical proteins requires further investigation.

Phages have natural, safe, and effective strategies to prevent and control multidrug-resistant bacteria, including against the ESKAPE pathogens Enterococcus faecium, Staphylococcus aureus, K. pneumoniae, A. baumannii, Pseudomonas aeruginosa, and Enterobacter spp. that exhibit multidrug resistance and
virulence. In this study, we have assessed the effect of phage BUCT541 against *K. pneumoniae* S-2007 *in vitro* and *in vivo*. *In vitro*, the number of *K. pneumoniae* S-2007 showed a trend of growth followed by decline and finally growth again, which is an arms race phenomenon between phage and host bacteria (Hampton et al., 2020). However, compared with the control group (without phage BUCT541), phage BUCT541 of different MOIs could significantly inhibit the growth rate of *K. pneumoniae* S-2007, especially at MOI = 10. It is possible that phage BUCT541 could be used as a biocontrol agent to contain the spread of *K. pneumoniae in vitro*. *In vivo*, the efficacy of phage BUCT541 against *K. pneumoniae* S-2007 was assessed in the *G. mellonella* and BALB/c mice. *G. mellonella* larvae have been widely used as a model because they are cheap and pose few ethical problems compared with other models (Insua et al., 2013; Wei et al., 2017). We found that the lower doses of BUCT541 phage (MOI = 1) had better therapeutic efficacy than the higher doses (MOI = 10) in *G. mellonella*. This finding is not entirely consistent with previous results that showed that the higher doses of phage led to higher survival rates of *G. mellonella* larvae (Wintachai et al., 2020). We suppose that the lysis of a large number of *K. pneumoniae* may have produced toxic substances such as endotoxin that caused the death of the *G. mellonella* larvae in our study (Luong et al., 2020; Wintachai et al., 2020). This seems to imply that higher phage titers may not always be more effective and the flexibility of phage titers should be considered in phage therapy. To further investigate the potential of phage BUCT541 for clinical application, we assessed the therapeutic effects of phage BUCT541 in BALB/c mice and the ability of BUCT541 to resist *K. pneumoniae* S-2007 in the lungs of mice. The high titer (2 × 10⁷ PFU/each, MOI = 10) of phage BUCT541 completely protects mice infected with *K. pneumoniae* S-2007, and this was quite different from the efficacy of treating *G. mellonella* larvae with high titer phage BUCT541. The different immune systems of the larvae and BLAB/c mice may explain this different outcome. After 30 h of treatment with phage BUCT541 (2 × 10⁷ PFU/each, MOI = 10), *K. pneumoniae* S-2007 in the lungs of mice was below 10⁴ CFU/mL, while *K. pneumoniae* S-2007 in the positive control group reached 10⁹ CFU/mL. It was shown that most of *K. pneumoniae* S-2007 could be cleared by BUCT541 in the mice lungs after 30 h treatment with phage BUCT541. The histopathologic examination of the mouse lungs also showed that phage BUCT541 effectively alleviated lesions caused by *K. pneumoniae* S-2007, and although BUCT541 caused a slight inflammatory response in the BALB/c mice, it did not affect the...
healthy life activity of the mice. These results suggest that phage BUCT541 can potentially be used as an alternative therapy for drug-resistant K. pneumoniae infection.

In conclusion, we characterized phage BUCT541 as a lytic phage against K1-ST23 K. pneumoniae. The bioinformatics analysis results and evaluation of therapeutic efficacy in G. mellonella larvae and BALB/c mice showed that phage BUCT541 has potential clinical applications in the treatment of K. pneumoniae infections.

Data availability statement

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/Supplementary material.

Ethics statement

The animal study was reviewed and approved by Ethics Review Committee of the Seventh Medical Center of the PLA General Hospital.

Author contributions

MP: resources, data curation, writing—original draft, and investigation. YL: resources, data curation, and investigation. PH and WL: resources and data curation. MP, YL, PH, WL, RG, FQ, XA, LS, and YT: data curation, investigation, and validation. ZC and SZ: supervision and writing—review and editing. HF: conceptualization and supervision. All authors contributed to the article and approved the submitted version.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmicb.2022.950737/full#supplementary-material

References

Ackermann, H. W. (2009). Phage classification and characterization. Methods Mol. Biol. 501, 127–140. doi: 10.1007/978-1-60327-164-6_13

Alam, T. I., and Rao, V. R. (2008). The ATPase domain of the large terminase protein, gp17, from bacteriophage T4 binds DNA: implications to the DNA packaging mechanism. J. Mol. Biol. 376, 1272–1281. doi: 10.1016/j.jmb.2007.12.041

Anand, T., Virmani, N., Kumar, S., Mohanty, A. K., Pavulraj, S., Bera, B. C., et al. (2020). Phage therapy for treatment of virulent Klebsiella pneumoniae infection in a mouse model. J. Glob. Antimicrob. Resist. 21, 34–41. doi: 10.1016/j.jgar.2019.09.018

Baase, W. A., Liu, L., Trounrud, D. E., and Matthews, B. W. (2010). Lessons from the lysozyme of phage T4. Protein Sci. 19, 631–641. doi: 10.1002/pro.344

Bao, J., Wu, N., Zeng, Y., Chen, L., Li, L., Yang, L., et al. (2020). Non-active antibiotic and bacteriophage synergism to successfully treat recurrent urinary tract infection caused by extensively drug-resistant Klebsiella pneumoniae. Emerg. Microbes Infect. 9, 771–774. doi: 10.1080/22221751.2020.1747950

Bortolaiia, V., Kaaas, R. S., Ruppe, E., Roberts, M. C., Schwarz, S., Cattoir, V., et al. (2020). ResFinder 4.0 for predictions of phenotypes from genotypes. J. Antimicrob. Chemother. 75, 3491–3500. doi: 10.1093/jac/dkaa345

Buttimore, C., Lucid, A., Neve, H., Franz, C., O’Mahony, J., Turner, D., et al. (2018). Pectobacterium atrosepticum phage vB_PatP_CBS: a member of the proposed genus ‘Phimunavirus’. Viruses 10, 394. doi: 10.3390/v10080394

Cafferey, D. P. (2010). Klebsiella pneumoniae carbapenemase-producing Enterobacteriaceae. J. Infect. Nurs. 33, 150–154. doi: 10.1097/NAN.0b013e3181d9c5ab

Cano, E. J., Cafiisch, K. M., Bolyky, P. L., Van Belleghem, J. D., Patel, R., Fackler, J., et al. (2021). Phage therapy for limb-threatening prosthetic knee Klebsiella pneumoniae infection: case report and in vitro characterization of anti-biofilm activity. Clin. Infect. Dis. 73, e144–e151. doi: 10.1093/cid/ciaa705

Chadha, P., Katare, O. P., and Chhibber, S. (2017). Liposome loaded phage cocktail: enhanced therapeutic potential in resolving Klebsiella pneumoniae mediated burn wound infections. Burns 43, 1532–1543. doi: 10.1016/j.burns.2017.03.029

Chung, D. R., Lee, H., Park, M. H., Jung, S. I., Chang, H. H., Kim, Y. S., et al. (2012). Fecal carriage of serotype K1 Klebsiella pneumoniae ST23 strains closely related to liver abscess isolates in Koreans living in Korea. Eur. J. Clin. Microbiol. Infect. Dis. 31, 481–486. doi: 10.1007/s10096-011-1334-7
Harada, S., Arki, K., Yamamoto, S., Ishii, Y., Sekiya, N., Kurai, H., et al. (2019). Clinical and molecular characteristics of Klebsiella pneumoniae isolates causing bloodstream infections in Japan: occurrence of hypervirulent infections in health care. J. Clin. Microbiol. 57, e1206-19. doi: 10.1128/JCM.02016-19

Hatfull, G. F., and Hendrix, R. W. (2011). Bacteriophages and their genomes. Curr. Opin. Virol. 1, 298–303. doi: 10.1016/j.coviro.2011.06.009

Heller, K., and Braun, V. (1979). Accelerated adsorption of bacteriophage T5 to Escherichia coli F, resulting from reversible tail fiber-lipopolysaccharide binding. J. Bacteriol. 139, 32–38. doi: 10.1128/JB.139.1.32-38.1979

Insua, J. L., Llovet, E., Moranta, D., Pérez-Gutiérrez, C., Tomás, A., Garmandea, J., et al. (2013). Modeling Klebsiella pneumoniae pathogenesis by infection of the wax moth Galleria mellonella. Infect. Immun. 81, 3552–3565. doi: 10.1128/IAI.00391-13

Ishiguro, T., Uozumi, R., Yoshioka, H., Nishida, T., and Takayangi, N. (2020). Comparison between patients with chest infection due to Klebsiella spp. and Strepptococcus pneumoniae. Int. Med. 59, 611–618. doi: 10.2169/internalmedicine.3531-19

Joensen, K. G., Scheutz, F., Lund, O., Hasman, H., Kaas, R. S., Nielsen, E. M., et al. (2014). Real-time whole-genome sequencing for routine typing, surveillance, and outbreak detection of verotoxigenic Escherichia coli. J. Clin. Microbiol. 52, 1501–1510. doi: 10.1128/JCM.03167-13

Karunarathna, K., Senathilake, N., Mewan, K. M., Weerasena, O., and Aparicio, T. (2018). A standardized workflow for surveying recombinases in microbiome encoding-capable habitats. Microbiol. Biotechnol. 11, 176–188. doi: 10.1111/1751-7915.12846

Rao, V. B., and Mitchell, S. M. (2001). The N-terminal ATPase site of the large packaging subunit gp17 is critically required for DNA packaging in bacteriophage T4. J. Mol. Biol. 314, 401–411. doi: 10.1006/jmbi.2001.5169

Rees, C. A., Smolinska, A., and Hill, J. E. (2016). The volatile metabolome of Klebsiella pneumoniae in human blood. J. Breath. Res. 10, 027101. doi: 10.1088/1752-7155/10/02/027101

Reyes, A., and Vives, M. J. (2020). Paving the way to unveil the diversity and evolution of phage genomes. Viruses 12, 905. doi: 10.3390/v12090905

Ricartue, D. E., Martínez-García, E., Nyes, Ā., Pāl, C., de Lorenzo, V., and Aparicio, T. (2018). A standardized workflow for surveying recombinases in microbiome encoding-capable habitats. Microbiol. Biotechnol. 11, 176–188. doi: 10.1111/1751-7915.12846

Rosh, D. R., and Donovan, D. M. (2015). Antimicrobial bacteriophage-derived proteins and therapeutic applications. Bacteriophage 5, e1062590. doi: 10.1128/bact.015701.2015

Russo, T. A., and Marr, C. M. (2019). Hypervirulent Klebsiella pneumoniae. Clin. Microbiol. Rev. 32, e00019-18. doi: 10.1128/cmrx.00019-18

Shu, Y., Chen, Y., Yang, Z., Zhang, Y., You, R., Liu, X., et al. (2020). Characterization and genome sequencing of a novel T7-like lytic phage, kqds, infecting carbapenem-resistant Klebsiella pneumoniae. Arch. Virol. 165, 97–104. doi: 10.1007/s00705-019-04447-y

SoFY, A. R., El-Doudoug, N. K., Refay, E. E., Dawoud, A. R., and Hmied, A. A. (2021). Characterization and full genome sequence of novel KF-5 lytic phage against Klebsiella pneumoniae responsible for recurrent infection. Biomedi. 9, 342. doi: 10.3390/biomedicines9040342

Sokolov, A. S., Latypov, O. R., Shlapakov, M. G., Bezlepkin, T. A., Khodol, N. S., et al. (2018). Phage T4 endonuclease SegD that is similar to group I intron endonucleases does not initiate homing of its own gene. Nucleic Acids Res. 46, 515–222. doi: 10.1093/nar/gzw121

Taschuk, F., and Cherry, S. (2020). DEAD-box helicases: sensors, regulators, and effectors for antiviral defense. Virus 12, 181. doi: 10.3390/v12020181

Uchiyama, J., Takemura, I., Sato, M., Kato, S., Ujihara, T., Akechi, K., et al. (2011). Improved adsorption of an Enterococcus facilliocase bacteriophage PFE24C with a spontaneous point mutation. PLoS ONE 6, e24648. doi: 10.1371/journal.pone.0024648

van Duijn, D., Cober, E., Richter, S. S., Perez, F., Kalayjian, R. C., Salata, R. A., et al. (2015). Residence in skilled nursing facilities is associated with tigecycline nonsusceptibility in carbapenem-resistant Klebsiella pneumoniae. Infection. Control Hosp. Epidemiol. 36, 942–948. doi: 10.1017/ice.2015.118

Wang, G., Zhao, G., Chao, X., Xie, L., and Wang, H. (2020). The characteristic of virulence, biofilm and antibiotic resistance of Klebsiella pneumoniae. Int. J. Environ. Res. Public Health 17, 6278. doi: 10.3390/ijerph17116278

Wei, W. J., Yang, H. F., Ye, Y., and Li, J. B. (2017). Galleria mellonella as a model system to assess the efficacy of antimicrobial agents against Klebsiella pneumoniae infection. J. Chemotherapy. 29, 252–256. doi: 10.1007/s10096-015-16589-2

Wilson, G. W., and Edgell, D. R. (2009). Phage T4 mobilizes trans homing of the deficient homing endonuclease I-TevII. Nucl. Acids Res. 37, 7110–7123. doi: 10.1093/nar/gkp769
Wintachai, P., Naknaen, A., Thammaphet, J., Pornwised, R., Phaonakrop, N., Roytrakul, S., et al. (2020). Characterization of extended-spectrum β-lactamase producing Klebsiella pneumoniae phage KP1801 and evaluation of therapeutic efficacy in vitro and in vivo. Sci. Rep. 10, 11803. doi: 10.1038/s41598-020-68702-y

Young, R. (2014). Phage lysis: three steps, three choices, one outcome. J. Microbiol. 52, 243–258. doi: 10.1007/s12275-014-4087-z

Zaki, A. (2019). Molecular study of Klebsiella pneumoniae virulence genes from patients with hospital acquired sepsis. Clin. Lab. 65:1. doi: 10.7754/Clin.Lab.2018.180709

Zhang, W., Zhang, R., Hu, Y., Liu, Y., Wang, L., An, X., et al. (2021). Biological characteristics and genomic analysis of a Stenotrophomonas maltophilia phage vB_SmaS_BUCT548. Virus Genes 57, 205–216. doi: 10.1007/s11262-020-01818-5

Zoledowska, S., Motyka-Pomagruk, A., Sledz, W., Mengoni, A., and Lojkowska, E. (2018). High genomic variability in the plant pathogenic bacterium Pectobacterium parmentieri deciphered from de novo assembled complete genomes. BMC Genom. 19, 751. doi: 10.1186/s12864-018-5140-9